Announcements Trials
Browse Landscape

Phase

Phase 2 14Phase 1 10Phase 3 5Phase 1/2 3Phase NA 2Phase 2/3 2Phase EARLY_PHASE1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Stomach Neoplasms 1Colorectal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Cisplatin 22Magnetic Resonance Spectroscopy 18Gemcitabine 14Carboplatin 14pembrolizumab 13Specimen Handling 13Paclitaxel 13Bevacizumab 11Radiotherapy 10Nivolumab 10atezolizumab 8Radiation 8Platinum 8Doxorubicin 8Docetaxel 81,2-diaminocyclohexaneplatinum II citrate 8Pemetrexed 7Drug Therapy 7Dexamethasone 7Temozolomide 6Ipilimumab 6Surgical Procedures, Operative 5Rituximab 5Radiotherapy, Intensity-Modulated 5Prednisone 5Cytarabine 5Cyclophosphamide 5Biopsy 5130-nm albumin-bound paclitaxel 5venetoclax 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Folfox protocol × 90 days × Clear all
NCT07221149 2026-05-14

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Bristol-Myers Squibb

Phase 2/3 Recruiting
690 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

NCT07221357 2026-05-06

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Bristol-Myers Squibb

Phase 2/3 Recruiting
990 enrolled
Gastrointestinal

Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡